Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03794440
Recruitment Status : Recruiting
First Posted : January 7, 2019
Last Update Posted : February 12, 2019
Sponsor:
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary:
The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Sintilimab Drug: IBI305 Drug: Sorafenib Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 566 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label,Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. (ORIENT-32)
Actual Study Start Date : February 11, 2019
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Sorafenib

Arm Intervention/treatment
Experimental: Sintilimab +IBI305 Drug: Sintilimab
200mg IV d1, Q3W
Other Name: IBI308

Drug: IBI305
15mg/kg IV d1, Q3W
Other Name: anti-VEGF monoclonal antibody

Active Comparator: Sorafenib Drug: Sorafenib
400mg PO BID




Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: up to 24 months after randomization ]
  2. Objective response rate (ORR) [ Time Frame: up to 24 months after randomization ]
    Objective response rate (ORR) in two arms based on RECIST V1.1 by Independent Radiological Review Committee,IRRC .


Secondary Outcome Measures :
  1. Disease control rate (DCR) [ Time Frame: up to 24 months after randomization ]
    DCR in two arms based on RECIST V1.1 by IRRC and investigator.

  2. Duration of response (DOR) [ Time Frame: up to 24 months after randomization ]
    DOR in two arms based on RECIST V1.1 by IRRC and investigator.

  3. Time to progression (TTP) [ Time Frame: One assessment was performed every 6 weeks (±7 days) from the time of randomization, and once every 12 weeks (±7 days) after 48 weeks. ]
    TTP in two arms based on RECIST V1.1 by IRRC and investigator.

  4. Time to response (TTR) [ Time Frame: up to 24 months after randomization ]
    TTR in two arms based on RECIST V1.1 by IRRC and investigator.

  5. Progression-free survival (PFS) [ Time Frame: 6 months ]
    PFS in two arms based on RECIST V1.1 by IRRC and investigator.

  6. Objective response rate (ORR) [ Time Frame: up to 24 months after randomization ]
    ORR in two arms based on RECIST V1.1 by investigator.

  7. Overall survival (OS) [ Time Frame: up to 24 months after randomization ]
  8. Anti-drug antibody (ADA) [ Time Frame: up to 24 months after randomization ]
    Immunogenicity measured by anti-drug antibody (ADA) for Sintilimab and IBI305.

  9. EORTC QLQ-C30 [ Time Frame: up to 24 months after randomization ]
  10. EORTC QLQ-HCC18 [ Time Frame: up to 24 months after randomization ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
  2. ECOG performance status between 0 and 1
  3. No systematic anti-tumor treatment has been performed.(End of postoperative adjuvant chemotherapy for more than 6 months allowed).
  4. Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment.
  5. At least 1 lesion with measurable disease at baseline by RECIST V1.1.
  6. Child-Pugh: <=7
  7. Adequate organ and bone marrow function.

Exclusion Criteria:

  1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
  2. Have a history of hepatic encephalopathy or have a history of liver transplantation.
  3. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
  4. Central nervous system (CNS) metastasis.
  5. Uncontrolled high blood pressure, systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg after optimal medical treatment.
  6. Local treatment for liver lesions within 4 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794440


Contacts
Layout table for location contacts
Contact: Qiu Yu +86-18625179461 qiu.yu@innoventbio.com

Locations
Layout table for location information
China, Shanghai
Hospital of Fudan University Recruiting
Shanghai, Shanghai, China, 200032
Contact: jia fan, M . D .    021-64041990    fan.jia@zs-hospital.sh.cn   
Contact: zhenggang ren, M . D .    021-60268615    ren.zhenggang@zs-hospital.sh.cn   
Sponsors and Collaborators
Innovent Biologics (Suzhou) Co. Ltd.

Layout table for additonal information
Responsible Party: Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov Identifier: NCT03794440    
Other Study ID Numbers: CIBI338B301
First Posted: January 7, 2019    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Sorafenib
Bevacizumab
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors